Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, #50 Ilwon-Dong Gangnam-Gu, 135-710, Seoul, Korea.
World J Surg Oncol. 2013 Feb 21;11:40. doi: 10.1186/1477-7819-11-40.
Hepatectomy is the standard treatment for HCC. However, large HCC poses a difficult challenge because of the technical complexity of surgical resection and the fear of postoperative hepatic decompensation. We analyzed the outcome and prognostic factors in patients with large hepatocellular carcinoma (HCC ≥10 cm) after surgery.
We retrospectively investigated the medical records of 91 patients who had undergone hepatectomy between January 2006 and June 2010. A survival analysis was performed utilizing the Kaplan-Meier method and prognostic factors were evaluated using Cox regression analysis.
Of the 91 patients evaluated, most tumors were associated with hepatitis B virus (HBV). The median tumor size was 12.3 cm (range, 10 to 21 cm), with microvascular invasion present in most patients. The postoperative mortality rate was 2.2%. The median disease-free survival and overall survival were six months and 41 months. The one-year, two-year, and three-year disease-free survival rates were 33.5%, 29.3%, and 18.8%, respectively. The one-year, two-year, and three-year overall survival rates were 73.9%, 63.7%, and 54.8%, respectively. Of the 89 surviving patients, 69 patients (77.5%) developed HCC recurrence during the mean follow-up period of 23.4 ± 15.9 months. On multivariate analysis, the statistically significant factors that predicted HCC recurrence were ALP ≥ 80 IU/mL (P = 0.009) and intrahepatic metastases (P = 0.013).
Our study suggests that preoperative ALP levels (≥ 80 IU/L) and intrahepatic metastases could be utilized to monitor and predict recurrence in HCC patients.
肝切除术是 HCC 的标准治疗方法。然而,由于手术切除的技术复杂性以及对术后肝功能失代偿的担忧,大肝癌的治疗具有挑战性。我们分析了手术后大肝癌(HCC≥10cm)患者的预后和预后因素。
我们回顾性分析了 2006 年 1 月至 2010 年 6 月期间接受肝切除术的 91 例患者的病历。采用 Kaplan-Meier 方法进行生存分析,应用 Cox 回归分析评估预后因素。
在 91 例患者中,大多数肿瘤与乙型肝炎病毒(HBV)相关。肿瘤中位大小为 12.3cm(范围为 10 至 21cm),大多数患者存在微血管侵犯。术后死亡率为 2.2%。中位无病生存期和总生存期分别为 6 个月和 41 个月。1 年、2 年和 3 年无病生存率分别为 33.5%、29.3%和 18.8%。1 年、2 年和 3 年总生存率分别为 73.9%、63.7%和 54.8%。在 89 例存活患者中,69 例(77.5%)在平均 23.4±15.9 个月的随访期间发生 HCC 复发。多因素分析显示,预测 HCC 复发的有统计学意义的因素是碱性磷酸酶(ALP)≥80IU/ml(P=0.009)和肝内转移(P=0.013)。
我们的研究表明,术前 ALP 水平(≥80IU/L)和肝内转移可用于监测和预测 HCC 患者的复发。